相关实验视频

Updated: Jan 15, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

全转网红酸作为血管化的预测剂和治疗剂

Jingqing Ma¹, Jingli Lu¹, Yanjun Lin¹

¹Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

|October 9, 2025

概括

低血清全转录氨酸 (ATRA) 水平与冠状动脉 (CAC) 评分相关. 通过减少沉积和炎症,ATRA补充剂可以有效治疗血管化.

科学领域:

心血管研究研究心血管研究
分子生物学分子生物学
营养科学营养科学

背景情况:

冠状动脉 (CAC) 是心血管事件的重要危险因素.
目前对CAC的诊断生物标志物和治疗策略有限.
全跨视网氨酸 (ATRA) 是维生素A的代谢物,在细胞发育和基因转录中起作用.

研究的目的:

研究患者血清ATRA水平和CAC得分之间的相关性.
探索ATRA补充剂在缓解血管化的潜力.
阐明ATRA对血管化的作用背后的分子机制.

主要方法:

在化条件下对大鼠血管光滑肌细胞 (VSMCs) 的蛋白质组分析.
测量88名人类患者的血清ATRA水平和CAC得分.
血管化的体内小鼠模型和体内VSMC化试验.
单细胞RNA测序小鼠大动脉以分析基因表达变化.

主要成果:

蛋白质组学揭示了化过程中ATRA合成酶的下调.
血清ATRA水平与CAC得分有负相关性 (AUC=0.9135).
在体内,ATRA补充剂减少了大动脉化,降低了RUNX2和BMP2的调节.
在体外,ATRA降低了VSMC中的沉积,TNF-α和IL-6.
单细胞RNA测序表明ATRA降低了VSMC中的TNF-α信号通路的调节.

结论:

低血清ATRA水平可能表明血管化.
补充ATRA证明了血管化的治疗潜力.
通过调节与炎症和化相关的通路,ATRA具有保护作用.

关键词:

阿加特斯顿的分数是多少全跨网红酸 (ATRA) 的使用.冠状动脉冠状动脉一个单细胞RNA测序.血管化血管化

更多相关视频

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Published on: January 27, 2023

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts

Published on: May 13, 2014

相关概念视频

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...